Background/Aims: Microalbuminuria is associated with diabetes and is an independent risk factor for developing diabetic nephropathy. We have previously reported the overall prevalence of normoalbuminuria, microalbuminuria, and macroalbuminuria to be 51, 39, and 9.8%, respectively, in an unselected population of patients with type 2 diabetes. Renal dysfunction was present in a large proportion of these patients without proteinuria, assessed by a single random albumin-to-creatinine ratio (ACR) . We therefore undertook to characterize the nature of this association of non-proteinuric renal dysfunction in type 2 diabetes. Methods: In the DEMAND (Developing Education on Microalbuminuria for Awareness of Renal and Cardiovascular Risk in Diabetes) study, a global, cross-sectional study which described the prevalence and risk factors for albuminuria in a clinic-based cohort, kidney function was assessed in 11,573 pa-
Introduction
It has been long recognized that microalbuminuria [urinary albumin excretion (UAE) between 30 and 300 mg/24 h] is associated with diabetes [1] and is an independent risk factor for both developing diabetic nephropathy and the occurrence of adverse cardiovascular events [2] [3] [4] . We have previously reported that in a global cohort of type 2 diabetes patients without known kidney disease, the overall prevalence of normoalbuminuria, microalbuminuria, and macroalbuminuria was 51, 39, and 9.8%, respectively [5] . Renal dysfunction was present in a large proportion of these subjects without proteinuria [assessed by albumin-tocreatinine ratio (ACR)]. We therefore aimed to characterize the nature of this association of non-proteinuric renal dysfunction in type 2 diabetes.
Patients and Methods
The DEMAND (Developing Education on Microalbuminuria for Awareness of Renal and Cardiovascular Risk in Diabetes) study design, methods, and principal results have been published previously [5] . Patients were included from North America, Europe, Africa, and Asia (see Appendix). Eligible patients were males and females aged 18-80 years with or without hypertension, type 2 diabetes mellitus (according to World Health Organization criteria) without a known history of proteinuria and/or diabetic kidney disease. A total of 32,208 subjects were evaluated, and after applying exclusion criteria (a history of kidney disease and/or proteinuria, invalid urine collections, absent nationality or region data, or absence of a single random ACR determination), 24,151 subjects were available for the study.
All participating general practitioners, physicians and nurses received the complete study protocol and were instructed to perform urinary ACR tests and blood pressure (BP) measurements with a sphygmomanometer after approximately 10 min of rest in the sitting position (single recording). Furthermore, demographics (age, gender, ethnicity, and region), clinical characteristics [height, body mass index (BMI), duration of diabetes, and hemoglobin A 1c (HbA 1c ), and serum creatinine (sCr) levels], medical history [family history of diabetes, hypertension, any cardiovascular disease (CVD); retinopathy; diabetic foot lesion; smoking, and hyperlipidemia], and concomitant treatments (glucose lowering, antihypertensive, lipid-lowering, and antiplatelet/anticoagulant treatment) were recorded on a single-page clinical report form for each patient. Data on the presence of CVD [coronary artery disease (CAD), myocardial infarction (MI), left ventricular hypertrophy (LVH), congestive heart failure (CHF), stroke, transient ischemic attack, or peripheral vascular disease (PVD)] were retrieved from medical records and information obtained during the interview. The presence of hyperlipidemia was based on objective measurements, as stated in the medical records. Arterial hypertension was considered present in patients receiving BP-lowering therapy. A single random urinary ACR was obtained using the semiquantitative reagent strip Multistix 10SG (Bayer AG, Leverkusen, Germany). According to this strip test, normoalbuminuria is defined as ACR ! 30 mg/g, microalbuminuria as 30-299 mg/g, and macroalbuminuria as 6 300 mg/g. According to the manufacturer, this test strip has a sensitivity of 84% and a specificity of 91% for ACR. Urine samples with creatinine concentrations ^ 10 mg/dl were discarded as too dilute, as prespecified in the protocol.
We used both the MDRD 4-variable formula [6] and the Cockcroft-Gault (CG) equation [7] to estimate kidney function [estimated glomerular filtration rate (eGFR) and estimated creatinine clearance (eCrCl), respectively]. The stages of chronic kidney disease (CKD) were defined according to the guidelines of the National Kidney Foundation (NKF) [8] .
Statistical Analysis
Univariate comparisons of the impact of independent variables on the average levels of continuous and categorical dependent variables were made using one-way analysis of variance and the 2 test, respectively. Data are presented as proportions for categorical variables and means 8 SD for continuous variables. Multivariable models predicting eCrCl, eCrCl ! 60 ml/min, and any history of CVD were created using the generalized linear model function [glm()] of S. All the variables adjusted in the models are prespecified, including age, BMI, race/ethnicity, region, sex, duration of diabetes, HbA 1c levels, smoking history, and duration of hypertension. Residuals from the linear regression model were assessed graphically for normality, and transformation on the dependent variable was done to correct non-normal residuals if needed.
Data analyses were performed using SAS for Windows (version 9.0; SAS Institute, Cary, N.C., USA) and S-Plus version 6.2 for Windows (Insightful Corp., Seattle, Wash., USA). A two-sided p ! 0.05 was required to reject the null hypothesis.
Results
In a total of 11,833 patients, sCr was available. Table 1 summarizes the patient characteristics with respect to the sCr measurement: 11,573 patients had complete data with which to estimate kidney function. Of these, CKD was noted in 1,044 of 6,072 patients with normoalbuminuria (17%; stage 3, 4, or 5 according to the NKF criteria); in 1,207 of 4,409 with Patien ts without data for a specified parameter were excluded. Means (SD) and numbers (%) are shown.
microalbuminuria (27%) and in 335 of 1,092 with overt proteinuria (31%). Table 2 shows the proportions of patients with each range of albuminuria, stratified by CKD stage. The percentages of patients (in whom measures of kidney function were available) with CKD stages 3, 4, or 5 and normoalbuminuria were 41, 26, and 29%, respectively. Table 3 shows renal and cardiovascular data stratified by level of albuminuria. In 24,151 patients, history of CVD was reported, but due to missing laboratory data, the presence of renal dysfunction was only evaluable in 11,315 patients. Decreased renal function (eCrCl ! 60 ml/min; determined by the CG formula) was noted in 20.5% of the patients with normoalbuminuria, while 30.7% of the patients with eCrCl ! 60 ml/min had microalbuminuria.
Albuminuria significantly correlated with decreased renal function at the time of assessment (measured by sCr and eCrCl) and estimates of kidney function below well-established cutoff points. Additionally, albuminuria correlated significantly with the presence of any CVD, and several individual components thereof (LVH, CHF, stroke, and CAD). However, a large number of patients with normal UAE or microalbuminuria had significant renal dysfunction (20.5 and 30.7%, respectively). Table 4 presents the predictors of renal function determined by logistic regression. Age and BMI contributed the greatest proportion of variance explained in the model, with age generating the greatest loss in eCrC (13.9 ml/min per 10 years; thus approximately 1.4 ml/ min per year), followed by Hispanic race (8.8 ml/ml in CrCl), the only significant racial contributor, and hypertension (2.4 ml/min in CrCl). Other factors significantly affecting eCrCl were duration of diabetes, diabetic retinopathy, hyperlipidemia, HbA 1c level, and anthropometric data. Table 5 presents the variables associated with eCrCl ! 60 ml/min. Age and BMI contributed the greatest proportion of deviance explained. UAE was associated with renal dysfunction [odds ratio (OR) 1.11, 95% confidence interval (CI) 1.08-1.14]. Other significant factors included Hispanic race, presence of diabetic retinopathy, male sex (which conferred an advantage), duration of diabetes, and location in North America. Table 6 shows that in our model of the variables associated with CVD, the greatest significant contributors to cardiovascular risk (composite and individual components) included age, history of hypertension, family history of CVD, hyperlipidemia, height, history of diabetic retinopathy, and duration of hypertension. Other factors (for example, albuminuria), although statistically significant, explained successively smaller proportions of the deviance and contributed little to the overall predicted risk.
A history of hypertension was strongly predictive of the presence of any CVD (OR 2.23, 95% CI 2.06-2.41), CAD (OR 2.25, 95% CI 2.02-2.52), and LVH (OR 3.53, 95% CI 2.95-4.22). There was a significant inverse correlation between diastolic BP and any CVD (OR 0.97 per 5 mm Hg, 95% CI 0.95-0.98), CAD, MI, CHF, and PVD.
African race was associated with a reduced risk (OR 0.50, 95% CI 0.35-0.71) of prevalent (reported) CVD compared to Caucasian race. A history of diabetic foot lesions was strongly correlated with the presence of PVD (OR 4.18, 95% CI 3.40-5.14). A reported family history of diabetes was protective for CVD (OR 0.82, 95% CI 0.77-0.88) and most of its individual components (CAD, MI, LVH, stroke, and PVD).
A history of smoking was associated with an increased risk of CAD (OR 
Discussion
This global, cross-sectional study examined the prevalence of albuminuria in a referred, clinic-or office-based study cohort. For these additional analyses, we chose to use the CG formula to estimate kidney function because of its greater accuracy over the MDRD equation at normal or near-normal levels of sCr [9] , since the great majority of our subjects (78%) had eGFR 6 60 ml/min/1.73 m 2 . Of note, these formulae were applied to populations in which they were not derived, but other more generalizable estimates of kidney function are lacking. Other newer estimates of kidney function [10] have not been validated in a global cohort.
The most striking finding in this cohort is the large number of diabetic subjects with decreased kidney function with completely normal UAE (20.5%, table 3 ) or microalbuminuria (30.7%). To our knowledge, this is the largest study performed to estimate this prevalence. Other studies have assessed this relationship in smaller (some prospective) cohorts [11] [12] [13] [14] [15] [16] [17] [18] , or excluded patients with diabetes [11] . Our results are in agreement with other prospective analyses [17, 18] . Previously, it has been suggested that normoalbuminuric diabetic subjects with renal dysfunction are less likely to progress to renal endpoints (in this case, death or dialysis) than their micro-or macroalbuminuric counterparts [12] .
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that induced by a single measurement) has diluted the proportion of variance explained by albuminuria in the regression analysis. Tables 4 and 5 present two methods of assessing predictors of renal function. In both cases, age and BMI contributed the largest cumulative proportion of variance and deviance, respectively. One must interpret this with caution, given the fact that age is a variable in the CG formula for eCrCl, and BMI is a function of weight, which is also a variable in this formula. Also, in this population of patients with albuminuria and renal dysfunction, many patients will succumb to cardiovascular events before a progressive decline in renal function presents [19] .
The failure of systolic BP to associate with the composite of cardiovascular variables may be explained by the strong effect of a history of hypertension in the model. Presumably, this variable takes patients receiving antihypertensive treatment into account and thus systolic BP is subsumed under it. Interestingly, an inverse relationship between diastolic BP and the risk of composite CVD has been reported in our [20] and other reports [21] . It appears that this protective effect for any CVD is largely determined by the protective effect for CAD, MI, and CHF, balanced by the risk of LVH. Additionally, renal function does not strongly associate with the composite cardiovascular variables, which may be explained by the fact that albuminuria does ( table 6 ) .
There is an interesting reduction in the risk of CVD in Africans compared to Caucasians, and for the African region compared to Europe. This may reflect more generally an increase in the risk of CVD reported in Caucasian Europeans, or may simply underscore the limitations of the reported history of any type of CVD. It may also reflect that Africans with a far shorter average life span die of other causes before CVD has the chance to surface.
Several possibilities exist that might explain our findings of renal dysfunction in the presence of minimal albuminuria or normal albuminuria. First, since data on drugs which block the renin-angiotensin system were not collected in the original DEMAND data, we cannot correlate proteinuria with the use of these agents; it may be that proteinuria has been reasonably well suppressed due to the use of these agents. However, although the rate of loss of renal function may be slowed by these agents, it may not be halted, despite the suppression of proteinuria. Hence, over time patients without significant albuminuria have decreased GFR and may progress to end-stage renal disease, although other non-diabetic renal diseases not prominently associated with albuminuria may be present [22] . Certainly, patients with diabetes and hypertension (and often underlying CVD) are at risk for hypertensive nephrosclerosis, tubulointersitial nephritis due to multidrug use (for example, non-steroidal antiinflammatory drugs) and episodes of acute kidney injury, which may result in incomplete recovery of renal function and may predict future CKD. This study cannot assess the presence or absence of any of these entities. Interestingly, a report of the pathologic lesions seen in type 2 diabetes argues in favor of two distinctive patterns of glomerular injury, namely Kimmelstiel-Wilson nodules and mesangial sclerosis [23] . Mesangial sclerosis has been reported to be associated with lower amounts of proteinuria compared to the KimmelstielWilson lesions, but long-term follow-up data are lacking in a large number of these patients [23] .
This study has the strength of being a large, international, multiracial cohort. However, it has several limitations, which are similar to those of the original DEMAND report. Albuminuria was estimated based on a single dipstick assessment of a spot urine specimen, and the variability in albumin excretion may dilute the proportion of variance attributed in the regression model. Likewise, kidney function was taken as a single measurement. However, by design, patients known to their physicians as having kidney disease were excluded. Additionally, all the information regarding coexisting disease was reported by the study physician, without independent review.
